TraitsThis product is a colorless, clear liquid.
Pharmacological effectsIt reduces renal tubular reabsorption and induces an increase in the urinary excretion of calcium, phosphorus and sodium. However, blood calcium does not decrease to below normal values. Calcitonin can reduce the secretion of gastric juice and exocrine pancreatic secretion, but does not affect peristalsis. Clinical trials have demonstrated that calcitonin has a pain-relieving effect, and research results have shown that there are specific binding sites for salmon calcitonin in the central nervous system.
Pharmacokinetics salmon calcitonin after intramuscular or subcutaneous injection, the absolute bioavailability of about 70%, the peak plasma concentration reached within 1 hour, the elimination half-life is 40-90 minutes. 95% of the drug is excreted by the kidneys, 2% in the original form, the apparent volume of distribution of 0.15-03 liters / kg, 30-40% is protein-bound.
IndicationsOsteoporosis. For early or late postmenopausal osteoporosis for which conventional estrogen/calcium combination therapy is contraindicated or otherwise unavailable. To prevent progressive bone marrow loss, patients on salmon calcitonin must be given supplemental calcium and vitamin D in appropriate amounts as needed.Paget's Bone Disease. Hypercalcemia secondary to breast, lung, myeloma, and other cancer metastases. Hyperparathyroidism, acute or chronic vitamin D toxicity. Painful neurotrophic dystrophy or Sudeck's disease. Often accompanied by a variety of causes and predisposing factors, such as traumatic osteoporosis, medical malnutrition, and burning pain.
Dosage Postmenopausal osteoporosis Injection : 50-100 IU daily, subcutaneously or intramuscularly, depending on severity of disease.Paget's disease Injection : 50-100 IU daily, subcutaneously or intramuscularly. Subcutaneous injections are well tolerated. Patients may give their own injections with reasonable guidance from their healthcare provider. In some cases, as little as 50 IU per day may be required; on the other hand, the daily dose may be increased to 200 IU (equivalent to 2 mL) if necessary. Hypercalcemia Emergency management of hypercalcemic crisis : Intravenous infusion is the most effective method of administration and should always be used in emergencies or severe cases. Dissolve 5-10 IU per kg per day in 500 ml saline and administer intravenously for at least 6 hours, or divide the daily dose into 2-4 slow intravenous injections. Supplemental administration of body fluids is necessary. Long-term management of chronic hypercalcemic states : Dose 5-10 IU per kilogram daily in 1 or 2 divided subcutaneous or intramuscular doses. If the dose exceeds 2 mL, it should be given intramuscularly at a different site. Painful neurotrophic dystrophy Early diagnosis is important and, once diagnosed, treatment with salmon calcitonin should be instituted as soon as possible. 100 IU daily, subcutaneously or intramuscularly for 2-4 weeks, then 100 IU three times weekly for more than 6 weeks.
Adverse effects nausea, vomiting, sensitivity to heat with mild facial flushing, and in some cases localized disturbances such as rhinitis, nasal leakage, sneezing, dryness or congestion of the nasal mucosa, and rhinorrhea. Calcium supplementation is theoretically necessary in hypotensive cases, and no drug cross-reactivity has been observed.
Contraindicated in patients who are hypersensitive to the product or to any of the components of the product.
Precautions 1. Contraindicated in patients with hypersensitivity to calcitonin. 2, Calcitonin clinical use must be carried out before the skin test, skin test method is as follows: (100 units/branch) with a T.B syringe to take 0.1 ml, diluted with saline to 1 ml, subcutaneous injection of 0.1 ml (about 1 unit), observation for 15 minutes, should not exceed the medium red is negative, more than the medium red is positive. 3, long-term bed-ridden patients, blood biochemistry and renal function should be checked every month, the patient is not allowed to take any medicine. Patients on long-term bed-ridden treatment should have their blood biochemistry and renal function checked every month.4. This product must be used under the supervision of a doctor.5. The safety data on the use of this product in children have not been established.
Interactions with other drugs have not been systematically studied.
Pregnant women and lactating women are contraindicated during pregnancy and lactation.
Children's UseThe drug should not be used in children for more than a few weeks unless a doctor requires its use for important medical reasons.